Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 14, 2025 • 6:00 PM ET

Date/Time Source News Release
09/06/2023 06:00 AM EDT GlobeNewswire BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
08/11/2023 09:00 AM EDT GlobeNewswire BiondVax Reports Second Quarter Financial Results and Provides Business Update
08/01/2023 04:01 PM EDT GlobeNewswire Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
07/11/2023 08:17 AM EDT GlobeNewswire IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
06/05/2023 07:00 AM EDT GlobeNewswire BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
05/15/2023 04:45 PM EDT ACCESSWIRE BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
04/17/2023 04:25 PM EDT GlobeNewswire BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
03/16/2023 01:10 PM EDT GlobeNewswire BiondVax to Present at BIO-Europe Spring
03/03/2023 02:07 PM EST GlobeNewswire IBN Announces 'Test. Optimize. Scale.' Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
02/02/2023 02:15 PM EST GlobeNewswire BiondVax Presenting at BIO CEO & Investor Conference
Page

Additional News

As of June 14, 2025 • 6:00 PM ET

Date/Time Source News Release
09/06/2023 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.
09/01/2023 03:00 PM EDT InvestorBrandNetwork BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
08/31/2023 01:45 PM EDT InvestorBrandNetwork Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes
08/28/2023 12:30 PM EDT InvestorBrandNetwork England Sees Soaring Numbers of Hospitalizations for Severe Allergies
08/25/2023 02:15 PM EDT InvestorBrandNetwork BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17
08/22/2023 04:00 PM EDT InvestorBrandNetwork How Allergy Sufferers Can Benefit from Immunotherapy
08/18/2023 01:00 PM EDT InvestorBrandNetwork Analyzing Link Between Hormonal Contraceptives, Autoimmunity
08/18/2023 09:45 AM EDT InvestorBrandNetwork BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
08/16/2023 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
08/15/2023 02:45 PM EDT InvestorBrandNetwork Stem Cell Transplants Followed by Immunotherapy Show Efficacy Against Pediatric Nerve Tumors
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.